82095

Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Daily Everolimus Plus Weekly Trastuzumab and Vinorelbine in Trastuzumab-Resistant, Advanced Breast Cancer (BOLERO-3)


More by Ruth O'Regan :